Glypican-3-binding fibronectin based scaffold molecules

US11524992B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Dasa Lipovsek · Pepperell, US
• Joseph Toth · Belmont, US
• Ginger C. Rakestraw · Somerville, US
• Irvith M. Carvajal · Somerville, US
• Stanley Krystek · Ringoes, US
• Steven O'Neil · Wayland, US
• Guodong Chen · East Brunswick Township, US
• Richard Y. Huang · Princeton, US
• Bryan C. BARNHART · San Francisco, US
• John Thomas Loffredo · Yardley, US
• Christina Terragni · Wilmington, US

Key dates

• Filing date: Jan 24, 2020
• Grant date: Dec 13, 2022
• Expiry date: Feb 19, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.